Related Experiment Video

Updated: May 14, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Medical management of stable coronary atherosclerosis

P Pellicori1, P Costanzo, A C Joseph

  • 1Academic Cardiology Unit, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, HU16 5JQ, UK.

Current Atherosclerosis Reports
|February 21, 2013
PubMed

Insights

Optimal medical therapy is crucial for stable coronary artery disease patients, reducing risks like heart attack. This review covers current treatments and new drug classes for coronary atherosclerosis management.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Stable coronary artery disease (CAD) management involves revascularization (coronary artery bypass grafting or percutaneous interventions) for symptomatic patients or those with extensive ischemia.
  • Optimal medical therapy is essential for all stable CAD patients to mitigate risks of adverse cardiac events, especially acute myocardial infarction.
  • The global burden of CAD necessitates active investigation into effective medical management strategies.

Purpose of the Study:

  • To review current medical management options for coronary atherosclerosis.
  • To discuss the role and future prospects of novel drug classes in treating stable CAD.
  • To outline future perspectives in the medical treatment of coronary artery disease.

Main Methods:

  • Literature review of current medical therapies for stable coronary artery disease.
  • Analysis of existing data on the efficacy of established and emerging pharmacological treatments.
  • Exploration of future trends and research directions in CAD medical management.

Main Results:

  • Established medical therapies are fundamental for risk reduction in stable CAD.
  • Newer drug classes show promise in improving outcomes and managing coronary atherosclerosis.
  • Personalized medical therapy combined with revascularization strategies offers the best approach for stable CAD.

Conclusions:

  • Optimal medical therapy is a cornerstone in managing stable coronary disease, regardless of revascularization.
  • Emerging pharmacological agents represent a significant advancement in treating coronary atherosclerosis.
  • Future research should focus on refining medical therapies and integrating them with revascularization for comprehensive CAD patient care.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...